The 2021 revised WHO guidelines reconstructed glioblastoma classification based on comprehensive molecular and genetic testing, in particular categorizing high-grade gliomas as IDH-mutant and IDH-wild-type based on isocitrate dehydrogenase gene mutation [30]. This evidence concerns the gene IDH3A and glioblastoma.